These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 24365090)

  • 21. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R; Ismail SM; Mohd Yunus N; Sulong S; Husin A; Abdullah AD; Hassan R
    Malays J Pathol; 2020 Dec; 42(3):307-321. PubMed ID: 33361712
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differences in Variants in the Structural Domain of BCR-ABL1 Kinase between Chinese Han and Minority Patients with Chronic Myeloid Leukemia by Sanger Sequencing and Next-Generation Sequencing.
    Abulaiti D; Tuerxun N; Wang H; Abulizi P; Zhao F; Liu Y; Hao J
    Cytogenet Genome Res; 2022; 162(4):201-206. PubMed ID: 36167055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
    Deininger MW; Hodgson JG; Shah NP; Cortes JE; Kim DW; Nicolini FE; Talpaz M; Baccarani M; Müller MC; Li J; Parker WT; Lustgarten S; Clackson T; Haluska FG; Guilhot F; Kantarjian HM; Soverini S; Hochhaus A; Hughes TP; Rivera VM; Branford S
    Blood; 2016 Feb; 127(6):703-12. PubMed ID: 26603839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pyrosequencing-based test for detection and relative quantification of the BCR-ABL1 T315I point mutation.
    Schumacher JA; Szankasi P; Bahler DW; Ho AK; Kelley TW
    J Clin Pathol; 2011 Jul; 64(7):618-25. PubMed ID: 21486895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
    Sánchez R; Dorado S; Ruíz-Heredia Y; Martín-Muñoz A; Rosa-Rosa JM; Ribera J; García O; Jimenez-Ubieto A; Carreño-Tarragona G; Linares M; Rufián L; Juárez A; Carrillo J; Espino MJ; Cáceres M; Expósito S; Cuevas B; Vanegas R; Casado LF; Torrent A; Zamora L; Mercadal S; Coll R; Cervera M; Morgades M; Hernández-Rivas JÁ; Bravo P; Serí C; Anguita E; Barragán E; Sargas C; Ferrer-Marín F; Sánchez-Calero J; Sevilla J; Ruíz E; Villalón L; Del Mar Herráez M; Riaza R; Magro E; Steegman JL; Wang C; de Toledo P; García-Gutiérrez V; Ayala R; Ribera JM; Barrio S; Martínez-López J
    Sci Rep; 2022 Jul; 12(1):13057. PubMed ID: 35906470
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational analysis in BCR-ABL1 positive leukemia by deep sequencing based on nanopore MinION technology.
    Minervini CF; Cumbo C; Orsini P; Anelli L; Zagaria A; Impera L; Coccaro N; Brunetti C; Minervini A; Casieri P; Tota G; Russo Rossi A; Specchia G; Albano F
    Exp Mol Pathol; 2017 Aug; 103(1):33-37. PubMed ID: 28663031
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCR-ABL1 kinase domain mutation analysis in an Irish cohort of chronic myeloid leukemia patients.
    McCarron SL; O'Connor LM; Langabeer SE; Conneally E
    Genet Test Mol Biomarkers; 2013 Feb; 17(2):170-3. PubMed ID: 23289634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing.
    Linhartova J; Hovorkova L; Soverini S; Benesova A; Jaruskova M; Klamova H; Zuna J; Machova Polakova K
    Mol Cancer; 2015 Apr; 14():89. PubMed ID: 25928096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
    Soverini S; De Santis S; Martelli M; Monaldi C; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Bruno S; Venturi C; Machova Polakova K; Ernst T; Maar D; Corner A; Cavo M
    Leukemia; 2022 Sep; 36(9):2250-2260. PubMed ID: 35908105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia.
    Soverini S; Branford S; Nicolini FE; Talpaz M; Deininger MW; Martinelli G; Müller MC; Radich JP; Shah NP
    Leuk Res; 2014 Jan; 38(1):10-20. PubMed ID: 24131888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.
    Ono T; Miyawaki S; Kimura F; Kanamori H; Ohtake S; Kitamura K; Fujita H; Sugiura I; Usuki K; Emi N; Tamaki S; Aoyama Y; Kaya H; Naoe T; Tadokoro K; Yamaguchi T; Ohno R; Ohnishi K;
    Leuk Res; 2011 May; 35(5):598-603. PubMed ID: 21239056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.
    Qin YZ; Huang XJ
    Methods Mol Biol; 2016; 1465():1-15. PubMed ID: 27581134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors.
    Chien SH; Liu HM; Chen PM; Ko PS; Lin JS; Chen YJ; Lee LH; Hsiao LT; Chiou TJ; Gau JP; Yang MH; Liu CY
    Hematol Oncol; 2020 Aug; 38(3):390-398. PubMed ID: 32011024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
    Baccarani M; Soverini S; De Benedittis C
    Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
    Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
    Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
    Egan DN; Beppu L; Radich JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Mascarenhas CC; Cunha AF; Miranda EC; Zulli R; Silveira RA; Costa FF; Pagnano KB; De Souza CA
    Leuk Lymphoma; 2009 Jul; 50(7):1148-54. PubMed ID: 19557636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
    Laudadio J; Deininger MW; Mauro MJ; Druker BJ; Press RD
    J Mol Diagn; 2008 Mar; 10(2):177-80. PubMed ID: 18276770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations.
    Bacher U; Haferlach T; Alpermann T; Zenger M; Hochhaus A; Beelen DW; Uppenkamp M; Rummel M; Kern W; Schnittger S; Haferlach C
    Br J Haematol; 2011 Mar; 152(6):713-20. PubMed ID: 21275954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.